JANSSEN RESEARCH & DEVELOPMENT, LLC

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

A Single and Multiple Dose Study to Investigate Safety, Tolerability and Pharmacokinetics of JNJ-42165279 in Healthy Japanese Male Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: JNJ-42165279
Drug: Placebo

First Posted Date: 2018-06-20

Last Posted Date: 2018-10-09

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 12

Registration Number: NCT03564379

Locations: 🇺🇸
WCCT Global, LLC, Cypress, California, United States

A Study to Explore the Efficacy of JNJ-67953964 in the Treatment of Depression

Phase 2

Completed

Conditions: Depressive Disorder, Major

Interventions: Drug: JNJ-67953964
Drug: Placebo

First Posted Date: 2018-06-18

Last Posted Date: 2023-06-26

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 181

Registration Number: NCT03559192

Locations: 🇺🇸
Psychiatric Medicine Associates LLC, Skokie, Illinois, United States
🇺🇸
Princeton Medical Institute, Princeton, New Jersey, United States
🇺🇸
Richmond Behavioural Associates, Staten Island, New York, United States

and more 46 locations

A Study of Cetrelimab (JNJ-63723283), a Programmed Cell Death Receptor-1 (PD-1) Inhibitor, Administered in Combination With Apalutamide in Participants With Metastatic Castration-Resistant Prostate Cancer

Phase 1

Completed

Conditions: Castration-Resistant Prostatic Neoplasms

Interventions: Drug: Cetrelimab 480 mg
Drug: Apalutamide 240 mg

First Posted Date: 2018-06-11

Last Posted Date: 2022-02-25

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 33

Registration Number: NCT03551782

Locations: 🇨🇦
University of Toronto, Toronto, Ontario, Canada
🇺🇸
Regional Urology LLC, Shreveport, Louisiana, United States
🇺🇸
University of California San Francisco (UCSF) - Prostate Cancer Center, San Francisco, California, United States

and more 31 locations

A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JNJ-64232025 in Healthy Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: JNJ-64232025 SC
Drug: JNJ-64232025 IV
Drug: Placebo

First Posted Date: 2018-06-11

Last Posted Date: 2019-02-27

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 48

Registration Number: NCT03550950

Locations: 🇧🇪
SGS Life Science Services, Antwerpen, Belgium

A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-Cell Maturation Antigen (BCMA) in Participants With Relapsed or Refractory Multiple Myeloma

Phase 1

Completed

Conditions: Multiple Myeloma

Interventions: Biological: JNJ-68284528

First Posted Date: 2018-06-07

Last Posted Date: 2024-04-02

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 126

Registration Number: NCT03548207

Locations: 🇺🇸
Mount Sinai Medical Center, New York, New York, United States
🇯🇵
University Hospital Kyoto Perfectural University of Medicine, Kyoto, Japan
🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

and more 18 locations

A Study to Evaluate JNJ-64565111 Pharmacokinetics and Safety in Adult Participants With Varying Degrees of Renal Function

Phase 1

Completed

Conditions: Kidney Failure, Chronic

Interventions: Drug: JNJ-64565111

First Posted Date: 2018-06-06

Last Posted Date: 2023-02-02

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 40

Registration Number: NCT03546205

Locations: 🇺🇸
AMR New Orleans, Formerly New Orleans Center for Clinical Research - New Orleans, an AMR company, Knoxville, Tennessee, United States
🇺🇸
Orlando Clinical Research Center, Orlando, Florida, United States

Fluoroquinolone Associated Disability

Completed

Conditions: Urinary Tract Infections
Bronchitis
Sinusitis

Interventions: Drug: Azithromycin (AZ)
Drug: Fluoroquinolone (FQ)
Drug: Sulfamethoxazole/Trimethoprim (ST) Fixed Dose Combination

First Posted Date: 2018-05-24

Last Posted Date: 2019-01-29

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 239306

Registration Number: NCT03535558

Locations: 🇺🇸
Janssen Investigative Site, Titusville, New Jersey, United States

A Study of Androgen Receptor (AR) Antagonist Apalutamide in Chinese Participants With Metastatic Castration-Resistant Prostate Cancer

Phase 1

Active, not recruiting

Conditions: Prostatic Neoplasms

Interventions: Drug: Apalutamide

First Posted Date: 2018-05-14

Last Posted Date: 2025-01-10

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 19

Registration Number: NCT03523442

Locations: 🇨🇳
Beijing Cancer Hospital of Peking University, Beijing, China
🇨🇳
Jiangsu Cancer Hospital, NanJing, China
🇨🇳
Peking University Third Hospital, Beijing, China

and more 1 locations

A Study of Ustekinumab in Participants With Active Systemic Lupus Erythematosus

Phase 3

Terminated

Conditions: Lupus Erythematosus, Systemic

Interventions: Drug: Ustekinumab (approximately 6 mg/kg)
Drug: Placebo
Drug: Ustekinumab 90 mg

First Posted Date: 2018-05-07

Last Posted Date: 2024-01-03

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 516

Registration Number: NCT03517722

Locations: 🇺🇸
Wallace Rheumatic Study Center, Los Angeles, California, United States
🇺🇸
Emory University, Atlanta, Georgia, United States
🇨🇦
Toronto Western Hospital, Toronto, Ontario, Canada

and more 201 locations

A Study of Bermekimab in Patients With Hidradenitis Suppurativa

Phase 2

Completed

Conditions: Hidradenitis Suppurativa

Interventions: Drug: Bermekimab Monoclonal Antibody 400 mg

First Posted Date: 2018-04-30

Last Posted Date: 2022-03-14

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 42

Registration Number: NCT03512275

Locations: 🇺🇸
Tennessee Clinical Research Center, Nashville, Tennessee, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy